Global Nausea Medicine Market Research Report—Forecast till 2027
The global Nausea Medicine Market is anticipated to witness a notable CAGR of 7.83% to surpass USD 2423.26 Million by the forecast period of 2027. Nausea medicines are used to treat conditions such as nausea and vomiting. The global market growth is attributed to the rising cases of cancer increase in gastrointestinal diseases, and growing geriatric population, sedentary lifestyle, and unhealthy diet.
The global Nausea Medicine Market is expected to register a healthy market growth during the review period owing to the increasing cases of cancer worldwide. The United States has more patients of cancer patients as per the study of the national cancer Institute approximately 1.8 Million people will be diagnosed with cancer in 2020. In 2017, as per the Cancer Research UK, in females in the UK, there were more than 179,000 new cancer cases and in males in the UK, there were around 187,000 new cancer cases that are likely to propel the market in the future. However, a high preference for home remedies is anticipated to restrain the growth of this market during the review period. Furthermore, collaborations between large drug manufacturing companies and small companies are expected to register the lucrative opportunity for the growth of the global Nausea market during the assessment period.
Global Nausea Medicine Market has been classified into Type, Mode of Administration, Indication, and Distribution Channel.
Based on the type, the nausea medicine market has been divided into antagonists, cannabinoids, antihistamines, and others. The nausea medicine market, in terms of the mode of administration category, is classified into oral, intravenous, and others. The nausea medicine market, based on indication, is classified into oncology, gastroesophageal reflux disease (GERD), motion sickness, and others. Based on distribution channels the market has been classified into hospital/retail pharmacies and online.
Based on indication, the oncology segment held the largest share of 39.84% in 2019 because of the rising number of patients experiencing nausea associated with chemotherapeutic drug use.
Geographically, Global Nausea Medicine Market has been classified into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is expected to lead the global nausea medicine market during the review period owing to the presence of major manufacturers, increasing awareness about early disease diagnosis, and the increasing prevalence of gastrointestinal diseases.
The European market is expected to register as the second-largest market for nausea medicine. The regional market is attributed to the biopharmaceutical sector, improving economies, high disposable income per individual, and increased healthcare spending market in this region.
The market in Asia-Pacific is anticipated to exhibit substantial market growth during the review period because of growing awareness about diseases, government support to improve the healthcare sector, and increasing geriatric population.
The Major Players in the Global Nausea Medicine Market are Novartis AG (Switzerland), Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline PLC (UK), Pfizer Inc. (US), Sanofi S.A. (France), Mylan NV (US), AstraZeneca (UK), Cipla Inc. (India), and others.
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.